Erschienen in:
01.08.2022 | Editorial
Light at the end of the tunnel?
Diagnostic and therapeutic strategies for heart failure with preserved ejection fraction
verfasst von:
Johann Bauersachs, Burkert Pieske
Erschienen in:
Herz
|
Ausgabe 4/2022
Einloggen, um Zugang zu erhalten
Excerpt
Heart failure was recognized for many decades by most internists and cardiologists as poor left ventricular systolic function, i.e., heart failure (HF) with reduced ejection fraction (HFrEF), resulting from ischemia, dilated cardiomyopathy, or valvular disease. Major trials, preferentially in patients with left ventricular (LV) ejection fraction (EF) < 40%, during the last 30 years have established evidence-based medical and device therapies for HFrEF translating into marked improvements in survival, symptoms, and quality of life as well as reduced HF worsening and hospitalization [
1]. …